, Volume 64, Issue 21, pp 2399–2416 | Cite as

Management of Acute and Chronic Gouty Arthritis

Present State-of-the-Art
  • Naomi SchlesingerEmail author
Review Article


There are three stages in the management of gout: (i) treating the acute attack; (ii) lowering excess stores of uric acid to prevent flares of gouty arthritis and to prevent tissue deposition of urate; and (iii) providing prophylaxis to prevent acute flares. It is important to distinguish between therapy to reduce acute inflammation in acute gout and therapy to manage hyperuricaemia in patients with chronic gouty arthritis.

During the acute gouty attack nonpharmacological treatments such as topical ice and rest of the inflamed joint are useful. NSAIDs are the preferred treatment in acute gout. The most important determinant of therapeutic success is not which NSAID is chosen, but rather how soon NSAID therapy is initiated. Other treatments include oral and intravenous colchicine, intra-articular and systemic corticosteroids, and intramuscular corticotropin.

Optimal treatment of chronic gout requires long-standing reduction in serum uric acid. The urate-lowering drugs used to treat chronic gout are the uricosuric drugs, the uricostatic drugs, which are xanthine oxidase inhibitors, and the uricolytic drugs. Xanthine oxidase inhibitors such as allopurinol, oxipurinol and febuxastat should be used as first-line treatment in patients with renal calculi, renal insufficiency, concomitant diuretic therapy and ciclosporin (cyclosporine) therapy, and urate overproduction. Uricosuric drugs include probenecid, benzbromarone, micronised fenofibrate and losartan. They are the urate-lowering drugs of choice in allopurinol-allergic patients and underexcretors with normal renal function and no history of urolithiasis. The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy.

The effectiveness of colchicine prophylaxis as an isolated therapy is still to be confirmed by placebo-controlled trials. Another issue is prophylaxis with NSAIDs. There are no comparative studies with colchicine.


Colchicine Gout Allopurinol Serum Uric Acid Serum Uric Acid Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author has served on the Febuxostat National Advisory Board. No sources of funding were used to assist in the preparation of this review.


  1. 1.
    Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421–6PubMedCrossRefGoogle Scholar
  2. 2.
    Yu TF, Gutman AB. Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 1967; 67: 1133–48PubMedGoogle Scholar
  3. 3.
    Wortmann RL. Effective management of gout: an analogy. Am J Med 1998 Dec; 105: 513–4PubMedCrossRefGoogle Scholar
  4. 4.
    Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970; 29: 461–8PubMedCrossRefGoogle Scholar
  5. 5.
    Weede RP. Poison in the pot: the legacy of lead. Carbondale (IL): Southern Illinois University Press, 1984: 83Google Scholar
  6. 6.
    Comrie JD, editor. Selected works of Thomas Syndenham MD with a short biography and explanatory notes. London: Bale J, Sons and Danielson, 1922Google Scholar
  7. 7.
    Bacethge BA, Work J, Landreneau MD, et al. Tophaceous gout in patients with renal transplantation treated with cyclosporine A. J Rheumatol 1993; 20: 718–200Google Scholar
  8. 8.
    Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout: report of six cases and review of the literature. Arch Intern Med 1992; 152: 873–6PubMedCrossRefGoogle Scholar
  9. 9.
    Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004–7PubMedCrossRefGoogle Scholar
  10. 10.
    Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritis and Musculoskeletal disease in the United States. J Rheumatol 1989; 16: 427–41PubMedGoogle Scholar
  11. 11.
    Mikkelson WH, Dodge HJ, Valkenberg H. The distribution of plasma uric acid values in a population unselected as to gout and hyperuricemia. Am J Med 1965; 39: 242–51CrossRefGoogle Scholar
  12. 12.
    O’Sullivan JB. Gout in a New England town: a prevalence study in Sudbury Massachusetts. Ann Rheum Dis 1972; 31: 166–9PubMedCrossRefGoogle Scholar
  13. 13.
    Perkins P, Jones AC. Gout. Ann Rheum Dis 1999; 58: 611–61PubMedCrossRefGoogle Scholar
  14. 14.
    Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974–9PubMedGoogle Scholar
  15. 15.
    Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Series 10. No. 200 [online]. Available from URL: [Accessed 2003 Jan 5]
  16. 16.
    Klemp P, Shelley A, Stansfield SA, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22–6PubMedCrossRefGoogle Scholar
  17. 17.
    Healy LA, Skeith MD, Decker JL, et al. Hyperuricemia in Filipinos: interaction of heredity and environment. Am J Hum Genet 1967; 19: 81–5Google Scholar
  18. 18.
    Schlesinger N, Baker DG, Beutler AM, et al. Acute gouty arthritis is seasonal. J Rheumatol 1998; 25: 342–4PubMedGoogle Scholar
  19. 19.
    Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979 Jun 28; 300(26): 1459–68PubMedCrossRefGoogle Scholar
  20. 20.
    Hall AP, Berry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med 1967; 42: 27–37PubMedCrossRefGoogle Scholar
  21. 21.
    Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47(6): 610–3PubMedCrossRefGoogle Scholar
  22. 22.
    McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54: 452–60PubMedGoogle Scholar
  23. 23.
    Lally EV, Zimmerman B, Ho G, et al. Urate mediated inflammation in nodal arthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989; 32: 86–90PubMedCrossRefGoogle Scholar
  24. 24.
    Reginato AJ, Schumacher Jr HR. Crystal associated arthropathies. Clin Geriatr Med 1988; 4: 295–322PubMedGoogle Scholar
  25. 25.
    Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med 1979; 92: 56–7Google Scholar
  26. 26.
    Bomalaski JS, Lluberas G, Schumacher Jr HR. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986; 29: 1480–4PubMedCrossRefGoogle Scholar
  27. 27.
    Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900PubMedCrossRefGoogle Scholar
  28. 28.
    Schlesinger N, Baker DG, Schumacher Jr HR. Gout: how well have diagnostic tests and therapies been evaluated? Curr Opin Orthop 2000; 11: 71–6CrossRefGoogle Scholar
  29. 29.
    Schlesinger N, Baker DG, Schumacher Jr HR. Gout: can management be improved? Curr Opin Rheumatol 2001; 13(3): 240–4PubMedCrossRefGoogle Scholar
  30. 30.
    Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kimmen. J Rheumatol 2000; 27: 1045–50PubMedGoogle Scholar
  31. 31.
    Lin KC, Lin HY, Chou P. The interaction between SUA level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501–5PubMedGoogle Scholar
  32. 32.
    Nicholas A, Scott JT. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 1972; II: 1223–4Google Scholar
  33. 33.
    Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350–5PubMedGoogle Scholar
  34. 34.
    Dessein PH, Shipton AE, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539–43PubMedCrossRefGoogle Scholar
  35. 35.
    Sharpe CR. A case controlled, study of alcohol consumption and drinking behaviour in patients with acute gout. CMAJ 1984; 131: 563–7Google Scholar
  36. 36.
    Agudelo CA, Schumacher Jr HR, Phelps P. Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis Rheum 1972; 15: 609–16PubMedCrossRefGoogle Scholar
  37. 37.
    Schumacher Jr HR. Crystal induced arthritis: an overview. Am J Med 1996; 100 Suppl. 2A: 46–52CrossRefGoogle Scholar
  38. 38.
    Schlesinger N, Baker DG, Beutler AM, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331–4PubMedGoogle Scholar
  39. 39.
    Dorwart BB, Hansell JR, Schumacher Jr HR. Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum 1974; 17: 563–71PubMedCrossRefGoogle Scholar
  40. 40.
    Pittman JR, Bross MH. Prognosis and management of gout. Am Fam Physician 1999; 59: 1799–806PubMedGoogle Scholar
  41. 41.
    Carew M, Roberts K. Care of the patient with gout. Geriatr Nurs 2000; 20: 156–7Google Scholar
  42. 42.
    Porter R, Rousseau GS, editors. Gout: the patrician malady. New Haven (CT): Yale University Press, 1998Google Scholar
  43. 43.
    Singer C. A history of scientific ideas. New York: Barnes and Noble Books, 1996Google Scholar
  44. 44.
    Peletier PS, Caventon J. [Title unknown]. Ann Chim Phys 1820; 14: 69Google Scholar
  45. 45.
    Corrodi H, Hardegger E. Die Konfiguration des Colchicins und verwandter Verbindungen. Helv Chem Acta 1955; 38: 2030–3CrossRefGoogle Scholar
  46. 46.
    Katzung BG, editor. Basic and clinical pharmacology. 6th ed. Norwalk (CT): Appleton and Lange, 1995: 536–59Google Scholar
  47. 47.
    Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991; 11: 196–211PubMedGoogle Scholar
  48. 48.
    Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Aust N Z J Med 1987; 17: 301–4PubMedCrossRefGoogle Scholar
  49. 49.
    Paulus HE, Schlosstein LH, Godfrey RC, et al. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1974; 17: 609–14PubMedCrossRefGoogle Scholar
  50. 50.
    British National Formulary 48. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2004 [online]. Available from URL: [Accessed 2004 Sep27]
  51. 51.
    Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003; 327: 1275–6PubMedCrossRefGoogle Scholar
  52. 52.
    Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine: guidelines for use. J Rheumatol 1988; 15: 495–9PubMedGoogle Scholar
  53. 53.
    Guazzo E. Use of intravenous colchicine for podagra [letter]. Am Fam Physician 1999; 60: 2504–5PubMedGoogle Scholar
  54. 54.
    Stephan WH. Use of intravenous colchicine in patients with acute gout [letter]. Am Fam Physician 2000; 61: 2343–4PubMedGoogle Scholar
  55. 55.
    Evans IT, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996; 23: 143–8PubMedGoogle Scholar
  56. 56.
    Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749–54PubMedCrossRefGoogle Scholar
  57. 57.
    Sandier DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165–72Google Scholar
  58. 58.
    Kelly W, Wortmann RL. Crystal-associated synovitis: gout and hyperuricemia. In: Kelly W, editor. Textbook of rheumatology. 4th ed. Philadelphia (PA): Saunders, 1993: 1340–51Google Scholar
  59. 59.
    Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973; 32(4): 351–3PubMedCrossRefGoogle Scholar
  60. 60.
    Ruosti A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative double-blind trial. Scand J Rheumatol Suppl 1978; 21: 15–7Google Scholar
  61. 61.
    Altaian RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422–6Google Scholar
  62. 62.
    Weiner GI, White SR, Weitzner RI, et al. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979; 22: 425–6PubMedCrossRefGoogle Scholar
  63. 63.
    Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26: 682–6PubMedCrossRefGoogle Scholar
  64. 64.
    Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12: 423–9PubMedCrossRefGoogle Scholar
  65. 65.
    Schumacher HR, Boice J, Dahikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92PubMedCrossRefGoogle Scholar
  66. 66.
    Gordon GV, Schumacher Jr HR. Management of gout. Am Fam Physician 1969; 10: 62–6Google Scholar
  67. 67.
    Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979; 10: 231–54CrossRefGoogle Scholar
  68. 68.
    Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285–6PubMedGoogle Scholar
  69. 69.
    Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329–36PubMedCrossRefGoogle Scholar
  70. 70.
    Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111–3PubMedGoogle Scholar
  71. 71.
    Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002 Oct; 46(10): 2765–75PubMedCrossRefGoogle Scholar
  72. 72.
    Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696–9PubMedGoogle Scholar
  73. 73.
    Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803–5PubMedCrossRefGoogle Scholar
  74. 74.
    Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994; 21: 1325–7PubMedGoogle Scholar
  75. 75.
    Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577–80PubMedGoogle Scholar
  76. 76.
    Gutman AB. Gout. In: Beeson PB, McDermott W, editors. Textbook of medicine. 12th ed. Philadelphia (PA): WB Saunders, 1958: 895Google Scholar
  77. 77.
    Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995; 22: 1621–3PubMedGoogle Scholar
  78. 78.
    Emmerson BT. The management of gout. N Engl J Med 1996; 334: 455–551Google Scholar
  79. 79.
    Ferraz MB. An evidence based appraisal of the management of tophaceous interval gout. J Rheumatol 1995; 22: 1618–20PubMedGoogle Scholar
  80. 80.
    Perez-Ruiz F, Alonso-Ruiz A, Calaabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57(9): 545–9PubMedCrossRefGoogle Scholar
  81. 81.
    Hepburn AL, Kaye SA, Feber MD. Fenofibrate is a new treatment of hyperuricemia and gout? Ann Rheum Dis 2001; 60: 984–6PubMedCrossRefGoogle Scholar
  82. 82.
    Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with hyperuricemia. Kidney Int 1999; 56: 1879–85PubMedCrossRefGoogle Scholar
  83. 83.
    Schumacher Jr HR, Moreno-Alvarez JM. Clued to common crystal induced arthropathies. Intern Med 1993; 14: 35–47Google Scholar
  84. 84.
    Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82–7PubMedCrossRefGoogle Scholar
  85. 85.
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76(1): 47–56PubMedCrossRefGoogle Scholar
  86. 86.
    Levinson DJ, Becker MA. Clinical gout and the pathogenesis of hyperuricemia. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. 12th ed. Philadelphia (PA): Lea and Febriger 1993: 1773–818Google Scholar
  87. 87.
    Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246–8PubMedGoogle Scholar
  88. 88.
    Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, febuxostat, in rodents. Eur J Pharmacol 1993; 241: 183–8PubMedCrossRefGoogle Scholar
  89. 89.
    Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor febuxostat in chimpanzees. Eur J Pharmacol 1993; 250: 455–60PubMedCrossRefGoogle Scholar
  90. 90.
    Swan S, Khosraven R, Mayer M, et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase [abstract]. Arthritis Rheum 2003; 48 Suppl. 9:529Google Scholar
  91. 91.
    Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout [abstract]. Arthritis Rheum 2002; 46 Suppl. 9: 289Google Scholar
  92. 92.
    Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988; 15: 1841–71PubMedGoogle Scholar
  93. 93.
    Medellin MV, Erickson AR, Enzenauer RJ. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol 1997; 3: 24–7PubMedCrossRefGoogle Scholar
  94. 94.
    Pawlotsky Y. What is the optimal treatment for acute crystal induced arthritis? Rev Rheum Engl Ed 1996; 63: 231–3Google Scholar
  95. 95.
    Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900PubMedCrossRefGoogle Scholar
  96. 96.
    Weinberger A, Pinkhas J. The efficacy of treatment with allopurinol versus uricosuric drugs in gout. Panminerva Med 1978 Jul–Sep; 20(3): 155–6PubMedGoogle Scholar
  97. 97.
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229–58PubMedGoogle Scholar
  98. 98.
    Beutler AM, Rull M, Schlesinger N, et al. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid [letter]. Clin Exp Rheumatol 2001; 19: 595PubMedGoogle Scholar
  99. 99.
    Scott JT. Comparison of allopurinol to probenecid. Ann Rheum Dis 1966; 25: 623–6PubMedGoogle Scholar
  100. 100.
    Altman A. Acute tumor lysis syndrome. Semin Oncol 2001; 28 (2 Suppl. 5): 3–8PubMedCrossRefGoogle Scholar
  101. 101.
    Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004 Jun; 6(3): 240–7PubMedCrossRefGoogle Scholar
  102. 102.
    Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 1981; 26: 49–53PubMedGoogle Scholar
  103. 103.
    Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002 Sep; 29(9): 1942–9PubMedGoogle Scholar
  104. 104.
    Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998; 28: 48–59PubMedCrossRefGoogle Scholar
  105. 105.
    Cohen A. Gout. Am J Med Sci 1936; 192: 448–93CrossRefGoogle Scholar
  106. 106.
    Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Ann Intern Med 1961; 55: 179–92PubMedGoogle Scholar
  107. 107.
    Yu TF. The efficacy of colchicine prophylaxis in articular gouta reappraisal after 20 years. Semin Arthritis Rheum 1982; 12: 258–64CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations